Instrument Inactif

Autres langues GTx, Inc. Nasdaq

Actions

US40052B1089

Recherche biotechnologique et médicale

Autres langues

01/07/25	Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO
01/07/25	Oncternal Therapeutics, Inc. Announces Management Changes
07/03/25	Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
05/12/24	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from S&P TMI Index
02/12/24	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from NASDAQ Composite Index
25/11/24	Top Premarket Decliners
25/11/24	Oncternal Therapeutics : Failure to Satisfy Listing Rule Form 8 K
06/11/24	Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
23/10/24	Oncternal Therapeutics Continues to Explore Strategic Alternatives
22/10/24	Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
22/10/24	Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
12/09/24	Oncternal Therapeutics, Inc. Announces Discontinue Its Clinical Trials Evaluating ONCT-534
12/09/24	Oncternal Therapeutics, Inc. Announces Workforce Reduction
12/09/24	Oncternal Therapeutics, Inc. Announces Cessation of Salim Yazji as Chief Medical Officer, Effective as of October 1, 2024
12/09/24	Sector Update: Health Care Stocks Rise in Thursday Trading
12/09/24	Oncternal Therapeutics Announces Exploration of Strategic Alternatives
12/09/24	Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall
12/09/24	Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
08/08/24	Oncternal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
08/08/24	Oncternal Therapeutics: Q2 Earnings Snapshot
08/08/24	Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
01/08/24	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
16/07/24	Oncternal Therapeutics : Corporate Presentation, July 2024
15/07/24	Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
15/07/24	Oncternal Therapeutics, Inc. Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer